Maze S S, Adolph R J
Department of Internal Medicine, University of Cincinnati Medical Center, Ohio 45267.
Clin Cardiol. 1990 Feb;13(2):69-79. doi: 10.1002/clc.4960130203.
Myocarditis is an enigmatic disease. Lymphocytic myocarditis is most commonly viral in origin. Considerable evidence suggests that myocardial damage is due to an immune-mediated mechanism rather than to direct effects of the virus itself. The presentation is variable, ranging from a clinically inapparent or relatively benign illness to acute progressive heart failure and death. Although examination of the endomyocardial biopsy specimen is the "gold standard" for the diagnosis of myocarditis there are problems with this technique, relating particularly to sampling error and histologic interpretation. Considerable evidence, both animal and human, suggests that a link between viral myocarditis and dilated cardiomyopathy does exist. There is a rational basis for the use of immunosuppressive therapy in myocarditis. Although many favorable responses have been reported with the use of these agents, the results of more definitive studies are awaited to determine the role of immunosuppressive therapy in myocarditis more clearly. Recommendations for the practical management of patients with myocarditis are made. Whenever possible, patients with this diagnosis should be entered into the ongoing NIH trial.
心肌炎是一种难以捉摸的疾病。淋巴细胞性心肌炎最常见的病因是病毒感染。大量证据表明,心肌损伤是由免疫介导机制引起的,而非病毒本身的直接作用。其临床表现多样,从临床上隐匿或相对良性的疾病到急性进行性心力衰竭及死亡。尽管心内膜心肌活检标本检查是心肌炎诊断的“金标准”,但该技术存在问题,尤其与取样误差和组织学解释有关。大量动物和人类研究证据表明,病毒性心肌炎与扩张型心肌病之间确实存在联系。在心肌炎中使用免疫抑制疗法有合理依据。尽管使用这些药物已有许多良好反应的报道,但仍有待更确切研究结果来更明确地确定免疫抑制疗法在心肌炎中的作用。文中给出了心肌炎患者实际管理的建议。只要有可能,诊断为此病的患者应纳入正在进行的美国国立卫生研究院试验。